Literature DB >> 7574514

Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.

R J Speirs1, J T Welch, M H Cynamon.   

Abstract

The mechanism of action of pyrazinamide (PZA) is not known. One hypothesis is that PZA functions as a prodrug of pyrazinoic acid. Susceptibility to PZA correlates with amidase activity of the Mycobacterium tuberculosis isolate in question. PZA-resistant isolates retain susceptibility in vitro to pyrazinoic acid and n-propyl pyrazinoate. Esters of pyrazinoic acid appear to circumvent the requirement for activation by mycobacterial amidase. The MICs of n-propyl pyrazinoate for M. tuberculosis isolates are lower than those of pyrazinoic acid. Further studies to assess the effects of modifications of the alcohol and pyrazine moieties of pyrazinoate esters on in vitro and in vivo antituberculosis activity are under way. This may lead to a candidate compound with enhanced activity against both PZA-susceptible and PZA-resistant M. tuberculosis isolates suitable for clinical development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574514      PMCID: PMC162725          DOI: 10.1128/AAC.39.6.1269

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.

Authors:  H F Lecoeur; C Truffot-Pernot; J H Grosset
Journal:  Am Rev Respir Dis       Date:  1989-11

2.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

3.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity.

Authors:  W R Butler; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

5.  Basis for lack of drug susceptibility of atypical mycobacteria.

Authors:  H L David
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

6.  Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig.

Authors:  F I DESSAU; R L YEAGER; F J BURGER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

7.  The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice.

Authors:  L MALONE; A SCHURR; H LINDH; D McKENZIE; J S KISER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

8.  Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Authors:  L B Heifets; M A Flory; P J Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 9.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  Development of a paper strip test for detection of niacin produced by mycobacteria.

Authors:  W D Young; A Maslansky; M S Lefar; D P Kronish
Journal:  Appl Microbiol       Date:  1970-12
View more
  22 in total

1.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia.

Authors:  H J Marttila; M Marjamäki; E Vyshnevskaya; B I Vyshnevskiy; T F Otten; A V Vasilyef; M K Viljanen
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories.

Authors:  Thomas R Ioerger; Yicheng Feng; Krishna Ganesula; Xiaohua Chen; Karen M Dobos; Sarah Fortune; William R Jacobs; Valerie Mizrahi; Tanya Parish; Eric Rubin; Chris Sassetti; James C Sacchettini
Journal:  J Bacteriol       Date:  2010-05-14       Impact factor: 3.490

3.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

Review 4.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

5.  Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.

Authors:  Brandon C Rosen; Nicholas A Dillon; Nicholas D Peterson; Yusuke Minato; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Introducing RpsA Point Mutations Δ438A and D123A into the Chromosome of Mycobacterium tuberculosis Confirms Their Role in Causing Resistance to Pyrazinamide.

Authors:  Wanliang Shi; Peng Cui; Hongxia Niu; Shuo Zhang; Tone Tønjum; Bingdong Zhu; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

7.  Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.

Authors:  S Sreevatsan; X Pan; Y Zhang; B N Kreiswirth; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.

Authors:  Susana Mendez; Ryan Traslavina; Meleana Hinchman; Lu Huang; Patricia Green; Michael H Cynamon; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

9.  High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Rokeya Tasneen; Paul O'Brien; Jansy Sarathy; Hassan Safi; Michael Pinn; David Alland; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Temperature-mediated heteroduplex analysis for detection of pncA mutations associated with pyrazinamide resistance and differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by denaturing high- performance liquid chromatography.

Authors:  Amr M Mohamed; Dhundy R Bastola; Glenn P Morlock; Robert C Cooksey; Steven H Hinrichs
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.